About Me

Dr. Jason G. Lewis

Jason’s passion is the discovery of differentiated therapeutics by data driven application of innovative chemistry. Most recently Jason joined Lycia Therapeutics as Vice President and Head of Chemistry in September 2020 as part of the founding leadership team.

At Lycia, Jason guided teams to refine the LYTAC approach conceived by founder Prof. Carolyn Bertozzi. Jason’s work allowed Lycia to focus strategy and realize the potential of the platform in the degradation of extracellular protein targets.

The chemistry group he led developed synthetic routes to enable practical scale-up of complex glycomimetic small molecule bioconjugates. Prior to that, he served as Vice President of Medicinal Chemistry at Ardelyx where he built a broad chemistry platform in GI selective therapeutics.

Since beginning his pharma carrier in 1992, Jason has also held positions with Gilead, Vicuron, Threshold Pharmaceuticals and worked in collaboration with Lilly, KKC, Astra Zeneca, Sanofi, Pfizer and Novartis. He graduated from Stanford with a B.S. in Biology and earned his Ph.D. in Chemistry at U.C. Berkeley under Prof. Paul A. Bartlett.

Jason’s numerous patents and publications span the areas of organic synthesis, protein degradation, small molecule conjugates of biologics, antimicrobials, targeted chemotherapy, therapeutic oligonucleotides, drug delivery, and novel ligands for GPCR and SLC transporter targets.